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The activation of immune-defense mechanisms in response to a microbial attack must be robust and appropriately tailored to fight particular types of pathogens. Infection with intracellular microorganisms elicits a type 1 inflammatory response characterized by mobilization of T helper type 1 (T H 1) cells to the site of infection, where they are responsible for the recruitment and activation of macrophages. At the center of the type 1 inflammatory response is the transcription factor T-bet, a critical regulator of the T H 1 differentiation program. T-bet induces the production of interferon-γ (IFN-γ) and orchestrates the T H 1 cell-migratory program by regulating the expression of chemokines and chemokine receptors. However, tight regulation of the type 1 inflammatory response is essential for the prevention of immunopathology and the development of organ-specific autoimmunity. In this review, we discuss how T-bet expression drives autoaggressive and inflammatory processes and how its function in vivo must be delicately balanced to avoid disease.
In 1986, Mosmann and Coffman made the landmark discovery that CD4 + T cells are not a homogenous cell population but can be categorized into the T helper type 1 (T H 1) and T H 2 subsets based on the cytokines that they secrete after being stimulated 1 . T H 1 cells make interferon-g (IFN-g) as their hallmark cytokine, whereas the T H 2 signature cytokines are interleukin 4 (IL-4), IL-5 and IL-13. After the introduction of the T H 1-T H 2 dichotomy to the immunology audience, considerable effort was made to discover the cytokine signaling pathways and transcription factors that initiate and stabilize commitment to the T H 1 or T H 2 lineage. This led to the identification of two major transcription factors, T-bet and GATA-3, as the master regulators of the T H 1 and T H 2 differentiation programs, respectively 2, 3 . The field of helper T cell biology has gone through another wave of renaissance-like rejuvenation with identification of a third effector helper T cell subset, T H 17 cells, characterized by the secretion of the following distinct panel of cytokines: IL-17A, IL-17F, IL-21 and IL- 22 (refs. 4,5) . T-bet has a unique role in the differentiation of all three subsets of helper T cells by promoting T H 1 differentiation while simultaneously inhibiting the opposing T H 2 and T H 17 lineagecommitment programs 2, [6] [7] [8] .
Naming T-bet 'T-box expressed in T cells' turned out to be a misnomer because subsequent studies showed that T-bet is expressed and has important roles in several immune-response cell types. As discussed below, the expression of T-bet in dendritic cells (DCs) is required for the priming of antigen-specific CD4 + T cells 9, 10 . T-bet-deficient CD8 + T cells produce less IFN-g and have diminished cytolytic activity 11 . In the absence of T-bet, B cells do not produce immunoglobulin G2a (IgG2a), and T-bet deficiency negatively affects the development and function of natural killer (NK) and NKT cells 12, 13 . Because T-bet is expressed in many cell lineages of the immune system, it is not surprising that its expression affects immunoregulation at many stages of the immune response. We have chosen several examples to demonstrate the complex role of T-bet in the immune response. Although T-bet expression is required for protection against pathogens, exuberant T-bet-regulated immune responses can be a driving force in inflammatory diseases. In contrast, silencing T-bet can also be pathogenic, as shown by greater susceptibility of T-bet-deficient animals to asthma and allergies.
T H 1 cells
In 2000, T-bet was isolated and shown to control the T H 1 genetic program in naive CD4 + T cells (Fig. 1) . T-bet directly activates Ifng (which encodes IFN-g), and ectopic expression of T-bet in fully differentiated T H 2 cells redirects them into the T H 1 lineage 2 . During the initial polarization phase, signaling via the T cell antigen receptor (TCR) and IFN-gtranscription factor STAT1 synergistically induces T-bet expression in helper T cell precursors [14] [15] [16] . Subsequent T-bet expression is driven by IL-12-STAT4 signaling in the absence of TCR stimulation 14, 16, 17 . In fact, cessation of TCR signaling is required for T-bet to induce expression of the IL-12 receptor b2 subunit and increase the responsiveness of T H 1 cells to IL-12, thus leading to further amplification of T-bet expression 17 .
By inducing IFN-g production in CD4 + T cells, T-bet can control many aspects of inflammation and immunoregulation. For example, IFN-g augments the antigen-processing and antigen-presenting ability of antigen-presenting cells, stimulates IgG2a production by B cells, induces the expression of cytokines and chemokines required for the recruitment of myeloid cells to the site of inflammation, and increases the expression of Toll-like receptors, nitric oxide synthase, and phagocyte oxidase by macrophages 18 . T-bet also orchestrates the T H 1 cell-migratory program by directly controlling expression of the chemokine receptor CXCR3 and the chemokines CCL3 and CCL4 (refs. 19,20 ; Fig. 1 ). The aforementioned mechanisms are components of a very effective type 1 response designed to sequester, contain and destroy the invading pathogen (Fig. 2) . Not surprisingly, deletion of the gene encoding T-bet (Tbx21) results in greater susceptibility to many intracellular has a pivotal role in driving the pathogenesis process. The following two main features distinguish Crohn's disease from ulcerative colitis: the location of inflammatory lesions, and the types of cytokines produced by helper T cells. The lesions in Crohn's disease are discontinuous, extend through multiple layers of the intestine and can affect both the small and large intestine. In contrast, ulcerative colitis is characterized by superficial mucosal ulcers restricted to the colon. Although Crohn's disease is associated with more production of T H 1 cytokines, such as IFN-g and tumor necrosis factor (TNF), T H 2 cytokines are thought to promote the immunopathology of ulcerative colitis [33] [34] [35] .
T-bet expression in T H 1 cells contributes to the pathogenesis of Crohn's disease. Several groups have detected more IFN-g production and higher T-bet protein expression in lamina propria CD4 + T cells from patients with Crohn's disease but not in those of patients with ulcerative colitis or healthy controls 25, 36 . Higher T-bet expression is also detected in T H 1-mediated mouse models of chronic intestinal inflammation but not in T H 2-mediated models. Although overexpression of T-bet in naive CD4 + T cells causes severe T H 1 cell-mediated chronic intestinal inflammation in immunocompromised mice, transfer of T-bet-deficient naive CD4 + T cells fails to induce this disease 25 . Interestingly, T-bet-deficient mice are more susceptible to oxazolone-induced, T H 2 cell-mediated colitis due to enhanced IL-4 production by T-bet-deficient lamina propria CD4 + T cells. Genetic elimination of STAT6 (T H 2-specific) signaling results in more production of IL-17A by Tbx21 -/-Stat6 -/-CD4 + T cells in the gut pathogens, including Mycobacterium tuberculosis 21 , Leishmania major 22 , Staphylococcus aureus 23 and Salmonella typhimurium 24 . However, it is easy to envision how these same mechanisms, when overactivated, could cause inflammation-associated tissue damage by autoreactive T H 1 cells. Hence, T-bet-deficient mice show greater resistance to the development of several inflammatory and autoimmune diseases, including inflammatory bowel disease 25 , experimental autoimmune encephalomyelitis (EAE) 26, 27 , arthritis 10 , systemic lupus erythematosus 12 and type 1 diabetes 9, 28 .
T-bet, T H 1 cells and immune responses to pathogens
The immune-response activities of T H 1 cells are mediated largely by the hallmark cytokine IFN-g (Fig. 2b) . Not surprisingly, mice deficient in IFN-g or its receptor are susceptible to an array of intracellular pathogens [29] [30] [31] . As T-bet has a pivotal role in the development of IFN-gproducing cells, several groups have examined the role of T-bet in infectious disease models. T-bet-deficient mice cannot clear L. major infection, as shown by their greater parasite burden and larger lesions 22 . T-bet-deficient CD4 + T cells isolated from mice infected with L. major produce much less IFN-g and have higher concentrations of the T H 2 cytokines IL-4 and IL-5. The shift to a T H 2 response accounts for the greater susceptibility of T-bet-deficient mice to L. major infection 22 . T-bet-deficient mice are also more susceptible to infection with M. tuberculosis or S. typhimurium than are wild-type control mice 21, 25 . As expected, IFN-g production by T-bet-deficient CD4 + T cells is much lower; however, in contrast to results obtained during L. major infection, in which there is a T H 2 bias, T-bet-deficient CD4 + T cells do not produce more IL-4 and IL-5 in response to infection with M. tuberculosis or S. typhimurium. Instead, they have more production of the immunosuppressive cytokine IL-10. Thus, T-bet expression is essential for resistance to infection with M. tuberculosis or S. typhimurium, a function that is mediated through the regulation of T H 1 differentiation and repression of IL-10 production 21, 24 . Tbx21 -/-mice are more susceptible to aerosol challenge with a Francisella tularensis live vaccine strain. Tbx21 -/-NK cells do not traffic to the lungs in response to infection with the F. tularensis live vaccine strain, so the early source of NK cell-derived IFN-g is absent and the very few IFN-g-producing CD4 + T cells that infiltrated the lung are unable to control bacterial replication (V.L. and L.H.G., unpublished data). Interestingly, T-bet is not required for host resistance to infection with Listeria monocytogenes. During such infection, the early IFN-g production by NK cells is not affected by the absence of T-bet 32 . Although IFN-g production by antigen-specific CD4 + T cells is lower, there is no defect in the generation of IFN-g-producing, antigen-specific CD8 + T cells. Hence, L. monocytogenes infection induces compensatory IFN-g production by NK cells and CD8 + T cells through T-bet-independent pathways, which is sufficient to control bacterial replication 32 . Thus, the role of T-bet in immune responses to most intracellular bacterial pathogens 'maps' mainly to its role in regulating the generation of a T H 1 response characterized by substantial induction of IFN-g production. In addition, T-bet expression in CD4 + T cells suppresses the expression of anti-inflammatory cytokines (such as IL-10) and T H 2 signature cytokines, which can skew the immune response to most pathogens from the protective T H 1 response to the susceptible T H 2 response.
T-bet, T H 1 cells and inflammatory and autoimmune diseases
Inflammatory bowel disease is a chronic inflammatory disease of the gastrointestinal tract that can present in two different forms: Crohn's disease and ulcerative colitis. Although the etiology of inflammatory bowel disease is not fully understood, it is suggested that deregulated cytokine production by cells of the immune system in response to gut microbiota
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Other studies have shown that T-bet is induced in fully differentiated T H 17 cells in response to IL-12 and type I-type II interferon signaling and is responsible for introducing repressive epigenetic changes in the locus encoding RORg (Rorc) that shut down RORgt expression 61, 62 . Consequently, T-bet-deficient mice have a higher frequency of T H 17 cells in several disease models [63] [64] [65] [66] . T-bet-deficient recipients develop accelerated rejection of cardiac allografts and vasculopathy despite their profound deficiency in IFN-gproducing CD4 + T cells 65 . Interestingly, the accelerated allograft rejection is associated with severe vascular inflammation characterized by infiltration of neutrophils and IL-17A-producing CD4 + cells. Neutralization of IL-17A prevents vascular inflammation and suppresses accelerated rejection of cardiac allografts in Tbx21 -/-mice. These results suggest that T-bet expression prevents the generation of CD4 + T H 17 cells able to mediate strong alloimmune responses, which cause allograft rejection 65 .
Tbx21 -/-mice are more susceptible to challenge with Trypanosome cruzi despite having a normal frequency of antigen-specific IFN-g T H 1 cells. The pathology is caused by the induction of a robust T H 17 response and chronic neutrophilia, which increases the morbidity and mortality of T. cruzi-infected mice. Similarly, T-bet-dependent signaling prevents T H 17 cell-mediated immunopathology in response to infection with Schistosoma mansoni 64 In an antigen-induced allergic airway inflammation model, Tbx21 -/-mice show more severe airway hyper-responsiveness that does not correlate with more production of T H 2 cytokines. Tbx21 -/-mice have higher concentrations of IL-17A than do control mice, which are associated with substantial influx of eosinophils and neutrophils into the lung 67, 68 . Neutralization of IL-17A results in less infiltration by neutrophils and less airway inflammation. Thus, T-bet prevents the development of allergies and asthma not only by inhibiting the differentiation of T H 2 cells but also by regulating the T H 1-T H 17 balance in the airways.
T-bet, T H 17 cells and autoimmune diseases
Rheumatoid arthritis is a chronic, inflammatory autoimmune disease that affects mainly the synovium of peripheral joints, although tissue damage can also encompass the lungs, pericardium and sclera. The inflammation of synovial tissue often leads to the destruction of articular cartilage, bone erosion and joint deformities. It was thought that T H 1 cells cause damage in the joints mainly through IFN-g-driven inflammatory mechanisms; however, conflicting data have been reported about the role of IFN-g in various animal models of rheumatoid arthritis. In some studies, IFN-g is actually protective. In the microbial S. aureus-induced sepsis and arthritis model, expression of T-bet and IFN-g results in lower incidence of the disease 23 . In collagen-induced arthritis, mice deficient mucosa and induction of T H 17 cell-dominant colitis 37 . These animal studies suggest that T-bet expression in CD4 + T cells delicately balances T H 1, T H 2 and T H 17 responses in the gut mucosal immune system 25 .
T-bet expression in CD4 + T cells also has a role in the pathogenesis of type 1 diabetes (Fig. 3) . This organ-specific autoimmune disease is caused by T cell-mediated destruction of the insulin-producing beta cells in the pancreas. Polymorphisms in TBX21 and T H 1-related genes have been linked in humans to a greater risk of developing type 1 diabetes. The T-bet Gln33 polymorphism, which is present at a greater frequency in Japanese patients with type 1 diabetes, is responsible for more transcription from the IFNG promoter, which suggests that T-bet-mediated control of IFN-g production is a contributing factor to the pathogenesis of this disease 38 . However, immunological analyses of mice deficient in IFN-g or its receptor suggest that this may not be the only mechanism 39, 40 . T-bet-deficient nonobese diabetic mice are fully protected from developing type 1 diabetes because of defects in both innate and adaptive immunity 9 . T-betdeficient DCs are impaired in priming naive CD4 + T cells. In addition, T-bet-deficient CD4 + T cells do not proliferate efficiently in vivo to generate enough autoreactive cells to cause diabetes. Loss of T-bet in CD4 + T cells also impairs their ability to migrate and, as a result, T-bet-deficient CD4 + cells infiltrate the pancreas poorly and promote diabetes less effectively 9 . Thus, T-bet expression in DCs is required for the initiation of autoimmune diabetes, whereas the pathogenic role of T-bet in CD4 + T cells is important during later stages of pathogenesis 9 (Fig. 3) .
T-bet, T H 2 cells and asthma
In addition to promoting the T H 1 developmental program, T-bet inhibits the differentiation of T H 2 cells 6 . The generation of T H 2 cells is dependent on IL-4-STAT6 signaling and upregulation of the T H 2 master regulator GATA-3 (refs. 3,41-43). T-bet blocks T H 2 differentiation in the following two ways: it directly inhibits expression of the T H 2-driving cytokine IL-4 (refs. 44, 45) , and it prevents GATA-3 from activating the Il5 and Il13 promoters 6 (Fig. 1) . The Il4 promoter and enhancer are hyper-acetylated in Tbx21 -/-CD4 + T H 1 cells, which reflects the suppressive effect of T-bet on the Il4 locus 45 . The mechanism of Il4 suppression also involves cooperative binding of the transcription factors Runx3 and T-bet at the Il4 silencer 44 . Phosphorylation of T-bet Tyr525 mediated by the kinase Itk is required for the interaction of T-bet with GATA-3 and sequestration of GATA-3 from the Il5 and Il13 promoters. Consequently, mice with targeted deletion of T-bet have a greater frequency of T H 2 cells and spontaneously develop an airway hyper-responsiveness associated with overproduction of T H 2 cytokines (IL-4, IL-5 and IL-13) and more peribronchial and perivenular infiltration by eosinophils and lymphocytes 46 . In this context, T-bet deficiency induces a pathological state in the lungs characterized by goblet cell hyperplasia, more collagen deposition and myofibroblast proliferation, which are indicative of the chronic airway remodeling often seen in patients with chronic asthma 46 . This remodeling is driven by the absence of T-bet-mediated repression of the pro-fibrotic cytokines IL-13 and transforming growth factor-b (TGF-b) 47 . In patients with asthma, T-bet expression by lung CD4 + T cells is much lower, and several different T-bet polymorphisms have been associated with allergic asthma 48, 49 . T-bet overexpression shifts the cytokine balance to the T H 1 response and attenuates goblet cell hyperplasia and mucus hyperproduction in mice after chronic allergen exposure 50 . Hence, similar to its role in the gut, T-bet controls the airway inflammatory response to environmental antigens by regulating the T H 1-T H 2 balance.
T-bet and T H 17 cell-mediated immunopathology
The differentiation of T H 17 cells is induced by TGF-b and IL-6 or IL-21, which upregulate expression of the T H 17 cell-specific transcription factor of multiple sclerosis, in which more T H 17 cells in the central nervous system (CNS) are not sufficient to elicit and sustain neuroinflammation in T-bet-deficient mice. These results suggest that the function of T-bet in the pathology of EAE and multiple sclerosis may not be straightforward 7 .
Multiple sclerosis is a chronic inflammatory disease of the CNS characterized by multifocal areas of leukocyte infiltration, demyelination and axonal damage that often result in paralysis. Components of cell-mediated and humorally mediated immunity were long thought to be involved in inducing and propagating neuroinflammation. Both T H 1 cells and T H 17 cells have been linked to multiple sclerosis, mainly through the production of their signature cytokines, IFN-g and IL-17A. However, there is some discrepancy between human multiple sclerosis and EAE in the role of IFN-g in disease pathogenesis. Patients with multiple sclerosis who have received recombinant IFN-g have a greater frequency of relapses and exacerbation of symptoms, which suggests that IFN-g contributes to the pathology of multiple sclerosis lesions 73 . That hypothesis has been supported by a clinical trial in which administration of neutralizing antibody to IFN-g has shown clinical benefits 74 . In contrast, mice deficient in IFN-g or its receptor develop exacerbated disease that has been attributed to less apoptosis of effector CD4 + T cells and a change in the composition of lymphocytic infiltration in the CNS 75, 76 . Interestingly, T-bet-deficient mice are protected from developing EAE, which indicates the existence of T-bet-dependent but IFN-g-independent mechanisms that contribute to disease development. Many studies have addressed the role T-bet in the pathology of EAE and multiple sclerosis, but the question of how T-bet expression drives autoreactive responses in the CNS still remains unanswered.
in the IFN-g receptor have an accelerated disease onset characterized by more infiltration of neutrophils and macrophages and severe destruction of tissues and bones 69, 70 . The disease is mild but not completely eliminated in IFN-g-deficient mice after immunization with proteoglycan. Eventually, IFN-g-deficient and T-bet-deficient mice succumb to arthritis because of much greater T H 17 responses that convert proteoglycaninduced arthritis, which is normally an IL-17A-independent model, into IL-17A-dependent arthritis 63 . The results from collagen-induced arthritis and proteoglycan-induced arthritis models would suggest that expression of IFN-g and T-bet has an immunomodulatory effect on the development of arthritis by constraining the magnitude of T H 17 responses (Fig. 4) .
Although the animal studies discussed above indicate T H 17 cells are the main culprit in disease initiation and progression, CD4 + T cells isolated from the joints of children with inflammatory arthritis have high expression of both RORgt and T-bet and produce both IL-17A and IFN-g 71 . The relationship between IL-17A and IFN-g is complex, and although animal studies suggest that IFN-g could be potentially used as a negative regulator of T H 17 cells, trials have not shown a substantial clinical benefit for recombinant human IFN-g in rheumatoid arthritis 72 . In the setting of rheumatoid arthritis, targeting the upstream mediators of T H 17 differentiation, such as IL-1, IL-6, IL-23 and TNF, or downstream effector functions of T H 17 cells involved in osteoclastogenesis and bone erosion may represent more effective therapeutic options.
In most of the disease models discussed above, T-bet deficiency is associated with more pathology due to deregulated T H 17 responses and heightened infiltration of neutrophils into target tissues. The exception to this rule is EAE, the most commonly used animal model So, how can the knowledge of transcription factors, cytokines and T cells be used to come up with better treatment strategies for multiple sclerosis? Mouse studies have shown that IFN-g is not required for development of EAE; however, data from studies of patients with multiple sclerosis should not be ignored. Although IFN-g is not the sole culprit in driving disease progression, targeting IFN-g can disrupt the T-bet + IFN-g + self-amplification loop and indirectly decrease T-bet expression in circulating lymphocytes. Targeting of T-bet directly, by inhibiting either its expression or its activity, has always been an attractive possibility, although transcription factors have proven to be a difficult class of proteins to target. However, given the widespread expression of T-bet in cells of the immune system, inhibition of T-bet may render patients immunocompromised. In that case, the options left are silencing T-bet in a cell-specific manner or targeting T-bet-regulated genes that contribute to the pathology of multiple sclerosis without substantially altering T-bet expression. Although much attention has been focused on CD4 + T cells, multiple sclerosis is not solely mediated by these cells. Conditional deletion of T-bet in various cell lineages will identify the importance of T-bet in pathogenic functions of other cells of the immune system and may lead to new potential therapeutic targets. 93 . The development of T reg cells is regulated by lineage-specific transcription factor Foxp3 (ref. 94); however, T-bet controls the expression of a subset of genes encoding molecules that influence the migration and homeostasis of T reg cells during T H 1 cell-mediated immune responses 93 . T-bet-deficient T reg cells cannot control T H 1 responses in the scurfy mouse model of autoimmunity 93 . However, the in vitro and in vivo T-bet is upregulated substantially in circulating CD4 + T cells and CD8 + T cells from the peripheral blood of patients with relapsing multiple sclerosis 77 . Brief treatment with a high dose of glucocorticoid has beneficial effects on the functional recovery of such patients 78 . Activated glucocorticoid receptors physically interact with T-bet and diminish its DNA-binding activity 79 . Glucocorticoid treatment results in much lower T-bet expression in CD4 + T cells and CD8 + T cells in patients with relapsing multiple sclerosis that correlates with the lower IFN-g production and improved clinical response 80 . Similarly, IFN-b treatment results in lower expression of IFN-g and T-bet in patients with relapsing multiple sclerosis; however, much lower T-bet expression is observed only in patients responsive to IFN-b treatment 81 . Thus, targeting T-bet expression in patients with multiple sclerosis could be therapeutically beneficial and could lead to amelioration of the disease by many mechanisms that may not be exclusively limited to IFN-g production.
T-bet and other helper T cells T-bet is also expressed in a subset of regulatory T cells (T reg cells)
Much attention has been directed to T H 17 cells and their role in multiple sclerosis because neutralization of IL-17A through genetic targeting or the administration of neutralizing antibodies results in lower disease severity [82] [83] [84] . However, T-bet-deficient mice, which have stronger T H 17 responses in the CNS than do wild-type mice, do not develop paralysis; this suggests that T H 17 cells and IL-17A are not sufficient to cause EAE in T-bet-deficient hosts 7, 85 . Some scientists argue that both T H 1 cells and T H 17 cells are needed to cause substantial damage in the CNS. For example, T H 17 cells are the first to infiltrate the CNS, and they are required for orchestration of the infiltration of T H 1 cells, which then initiate and sustain neuroinflammation 86 . Alternatively, polyfunctional CD4 + T cells that simultaneously produce IL-17A and IFN-g may be more pathogenic than CD4 + T cells that produce either IL-17A or IFN-g. There is some evidence to suggest that cells producing both IL-17A and IFN-g may be better equipped for transmigration across the blood-brain barrier than are cells producing either IL-17A or IFN-g. Upregulation of the integrin ligand ICAM-1 in response to IFN-g, combined with the barrier-disrupting effects of IL-17A, could contribute to the greater migratory ability of IFN-g-producing T H 17 cells 87 .
IFN-g-producing T H 17 cells with dual expression of T-bet and RORgt have also been detected in the CNS of mice with EAE 88, 89 . Although animal studies have shown that T H 17 cells are a distinct lineage in their own right, these cells have a great deal of flexibility and plasticity and acquire a T H 1-like phenotype quickly after exposure to IL-12 or IL-23. This acquisition of a T H 1-like phenotype is dependent on T-bet and STAT4 and involves the introduction of repressive epigenetic changes in the Rorc locus of T H 17 cells 61 . Although T-bet limits the magnitude of T H 17 cell responses, T-bet-deficient T H 17 cells are not pathogenic 85 . These observations suggest that T-bet may have complex regulatory roles in T H 17 biology; it has a negative role because it restrains the amount of IL-17A produced by T H 17 cells and has a positive role by controlling a gene or a subset of genes required for the encephalitogenic potential of T H 17 cells. As IFN-g and IL-17A-IL-17F are dispensable for the propagation of neuroinflammation, the 'genetic fingerprint' that renders a cell pathogenic remains unknown. The following three factors have been shown to be important for the encephalitogenic potential of CD4 + T cells: IL-23, STAT4 and T-bet 26, 90, 91 . We propose here that T-bet has a central role along with IL-23 and STAT4, converging on the same signaling pathway that ultimately results in the induction of T-bet. In support of our hypothesis is an elegant study of fate mapping of IL-17-producing T cells showing that IL-23 is key for the induction of T-bet, expression of both IL-17A and IFN-g and subsequent deviation to a T H 1-like phenotype 92 . These IL-23-induced T-bet-expressing T H 17 cells have greater encephalitogenic potential than do 'regular' T H 17 cells 89 . It remains to be demonstrated whether STAT4 is phosphorylated in T H 17 cells in response to signaling through the IL-23 receptor and whether STAT4 Katie vicari IL-15 receptor b-subunit) and for specifying IL-15 responsiveness 103 . These results suggest that T-bet and eomesodermin have cooperative and partially redundant functions in regulating both IL-15-mediated homeostasis and the transcriptional program of cytolytic T lymphocytes. Furthermore, a gradient of T-bet expression specifies a short-lived effector cell fate or memory precursor effector cell fate. Under inflammatory conditions, high T-bet expression promotes the generation of terminally differentiated short-lived effector cells with a KLRG hi IL-7R lo phenotype. In contrast, CD8 + T cells with small amounts of T-bet will develop into long-lived, self-renewing memory CD8 + T cells 105 . It has been shown that IL-12-augmented activity of the kinase mTOR is essential for sustained T-bet expression and the generation of effector CD8 + T cells 106 . The treatment of IL-12-conditioned CD8 + T cells with rapamycin, a chemical inhibitor of mTOR activity, blocks T-bet expression and promotes sustained eomesodermin expression. Higher eomesodermin expression in CD8 + T cells enhances the generation of long-lived, memory CD8 + T cells. Thus, balance between the transcription factors T-bet and eomesodermin, as 'instructed' by mTOR activity, can determine the CD8 + effector cell fate versus memory cell fate 106 . T-bet expression in CD8 + T cells is required for the generation of CD8 + T cell-dependent autoimmune diabetes 28 . In the RIP-LCMV mouse model, lymphocytic choriomeningitis virus (LCMV) antigens are transgenically expressed in pancreatic beta cells under control of the rat insulin promoter 107, 108 . CD8 + T cell-dependent autoimmune diabetes is rapidly induced in these mice after infection with LCMV. Notably, the virus is cleared from these mice before the onset of autoimmune diabetes. Islet destruction is dependent on concomitant production of TNF and IFN-g and the cytotoxic function of CD8 + T cells (Fig. 3) . In this model, primary antiviral CD8 + T cell responses develop normally in T-bet-deficient mice. However, there is a profound and intrinsic defect in the generation of effector-memory CD8 + T cell responses specific for suppressive functions of T reg cells are unaffected by the loss of T-bet 25, 26, 47, 95 . Tbx21 -/-T reg cells show a stronger protective effect in T H 1 cell-mediated colitis than do wild-type T reg cells, and the enhanced protective effect is associated with augmented TGF-b production 25 . Tbx21 -/-T reg cells are as potent as wild-type T reg cells in preventing innate immunity-driven ulcerative colitis and autoimmune diabetes 8, 95 . The observed discrepancies in the role of T-bet in T reg cells could be explained by the different inflammatory disease models used to test T reg cell function. Foxp3-deficient scurfy mice succumb to severe, systemic multiorgan autoimmunity, and under these overwhelming inflammatory conditions, the suppressive function of T-bet-deficient T reg cells may be compromised. In contrast, in other models focused on testing the function of T reg cells in organ-restricted inflammatory or autoimmune diseases, T-bet deficiency in T reg cells has no effect on their suppressive functions. Future studies will clarify the role of T-bet in the biology of T reg cells under different inflammatory conditions.
The activation of naive CD4 + T cells in the presence of IL-4 and TGF-b results in development of CD4 + helper T cells producing both IL-9 and IL-10 (T H 9 cells) that are inflammatory despite having more IL-10 production 96, 97 . T H 9 cells are able to induce EAE in an adoptivetransfer model, and when transferred along with CD45RB hi CD4 + T cells, T H 9 cells induce colitis and peripheral neuritis in recipients deficient in recombination-activating gene 1 (Rag1) 96, 98 . Because IL-9 is very important in intestinal responses to helminthes, T H 9 cells are important in protective immunity to Trichuris muris 97 . T-bet is not expressed in T H 9 cells differentiated in vitro 96, 97 . However, in a passive EAE model and in a T cell-transfer model of colitis, these T H 9 cells regain the ability to produce IFN-g, analogous to the plasticity of T H 17 cells 96, 98 . Hence, it would be interesting to see how T-bet deficiency or T-bet expression influences the development and effector functions of these cells.
Initially it was proposed that the main function of CD4 + helper T cells is to provide 'help' to B cells by regulating their proliferation and immunoglobulin class switching. A particular subset of CD4 + T cells, follicular helper T cells (T FH cells), is found in the germinal centers whose specialized functions promote B cell-mediated humoral immunity. The development of T FH cells is critically dependent on IL-6, IL-21 and STAT3, which induce expression of the T FH cell-specific transcription factor Bcl-6 (refs. 99,100). Although T FH cells do not express T-bet, it is interesting that T-bet-deficient mice have poor IgG2a responses. This observation warrants more complete investigation of a potential role for T-bet in the development of T FH cells and the outcome of T FH cell-B cell interactions.
T-bet expression promotes the development of proinflammatory diseases mediated by T H 1 cells; however, T-bet deficiency can also cause pathological changes characterized by overexuberant T H 2 and T H 17 responses due to the loss of T-bet-mediated negative regulatory mechanisms. Hence, precise calibration of T-bet in CD4 + T cells is essential for maintenance of immunological homeostasis.
T-bet in other cells of the immune system CD8 + T cells have a critical role in antiviral and antitumor immunity. T-bet and eomesodermin regulate the transcriptional program of effector cytolytic T lymphocytes 101, 102 (Fig. 2a) . Overexpression of eomesodermin or T-bet is sufficient to induce the expression of IFN-g, perforin and granzyme B in CD8 + T cells and, conversely, expression of dominant negative mutants of eomesodermin or T-bet results in less IFN-g production and granzyme B expression 102 . Mice with the combined loss of Tbx21 and the gene encoding eomesodermin (Eomes) have additive defects in the expression of cytolytic T lymphocyte-associated genes and also lack memory CD8 + T cells 103, 104 . The expression of T-bet and eomesodermin is required for high expression of CD122 (the IL-2 and Katie vicari mice are functionally immature and hyperactivated and undergo more apoptosis 13 . T-bet expression is required for the cytotoxic activity and sustained IFN-g production of NK cells in response to infection with murine cytomegalovirus 13 . T-bet deficiency in NK cells severely compromises antitumor responses and results in greater susceptibility to metastatic melanoma 113 . The transfer of wild-type NK cells protects Tbx21 -/-mice from the metastasis of melanoma to the lungs. The lungs of Tbx21 -/-mice have a considerable deficiency in NK cells in after melanoma challenge that is not associated with trafficking defects but instead reflects less survival of T-bet-deficient NK cells. The very few remaining Tbx21 -/-NK cells have impaired IFN-g production and cytotoxic activity 113 . These results suggest that augmented T-bet expression in NK cells may enhance antitumor responses and affect tumor metastasis. DCs rapidly upregulate T-bet in response to IFN-g and Toll-like receptor 9 signaling 114 (Fig. 2a) . T-bet is essential for optimal production of IFN-g by DCs and for the priming of T H 1 cells 114, 115 . DCs genetically engineered to have high expression of T-bet promote the priming of T H 1 and cytotoxic T cell type 1 responses independently of . Naive CD4 + T cells and CD8 + T cells have higher cell surface expression of CXCR3 and IL-12 receptor b2, express more granzyme B and produce higher concentrations of IFN-g when primed with T-bet-overexpressing DCs versus than when primed with control DCs 116 . Hence, DCs modified to overexpress T-bet could be potentially used to boost antitumor immunity.
T-bet in DCs has a pivotal role in modulating host-commensal relationships in the gastrointestinal tract through its regulation of TNF production by colonic DCs 95 . T-bet binds to the Tnf promoter and inhibits Tnf promoter activity driven by the transcription factor NF-kB in a dose-dependent manner. Loss of T-bet in immunocompromised mice (Tbx21 -/-Rag2 -/-mice) causes deregulated TNF production by colonic DCs and more apoptosis of gut epithelial cells. These events lead to the breakdown of the intestinal epithelial barrier and continuous influx of gut bacteria into the underlying mucosal tissue, which fuels more TNF production and inflammation. The cytokine-driven inflammation in the gut of Tbx21 -/-Rag2 -/-mice represents a unique environment conducive for the generation and expansion of colitogenic bacteria, which can then infect immunocompetent hosts and initiate and perpetuate chronic gut inflammation independently of T-bet 95 . These studies raise several important questions. What is the role of the immune system in shaping the composition of microbial flora in the gut? Can the host microbial community instigate and drive inflammatory diseases in humans? Can chronic intestinal inflammation be stopped with immunotherapy or by the colonization of a host with beneficial bacteria? Studies have shown that the inclusion of probiotic bacteria in the diet alleviates colonic inflammation 117 . Furthermore, restoring T-bet expression specifically in DCs efficiently lowers TNF production and prevents the development of colitis and colitis-associated colorectal cancer in Tbx21 -/-Rag2 -/-mice 118 . Better understanding of how T-bet regulates biological processes in cells of adaptive and innate immune systems in the context of intestinal inflammation is required for the identification of new ways of interfering with T-bet-mediated inflammatory pathways in cells of the adaptive immune response while preserving the immunoregulatory role of T-bet in DCs.
T-bet expression in DCs is also required for the initiation and progression of rheumatoid arthritis (Fig. 4) . Several aspects of DC biology can contribute to the pathogenesis of rheumatoid arthritis, including the priming of autoreactive T H 1 cells and T H 17 cells and the production of chemokines and proinflammatory cytokines such as IL-1, IL-6 and TNF. T-bet-deficient mice are protected in the passive collagen antibodyinduced arthritis model, in which the importance of T-bet expression has been 'mapped' to DC function 10 . Adoptive transfer of T-bet expressing LCMV-derived antigens 28 . As a result, T-bet-deficient mice are very well protected from developing type 1 diabetes. This observation indicates T-bet as a potential therapeutic target for the treatment of autoimmune diabetes 28 .
The functional importance of T-bet expression in CD8 + T cells is also highlighted by the greater susceptibility of T-bet-deficient mice to LCMV, whose clearance is largely dependent on CD8 + T cells 11 . T-betdeficient CD8 + T cells have compromised cytolytic activity and many fewer IFN-g-producing CD8 + T cells. These impaired effector functions of Tbx21 -/-CD8 + T cells provide inadequate protection against LCMV infection and result in greater susceptibility of Tbx21 -/-mice to LCMV 11 . Interestingly, mice with double deficiency in T-bet and eomesodermin (Tbx21 -/-Eomes -/-mice) develop a progressive inflammatory and wasting syndrome characterized by multiorgan infiltration of neutrophils after infection with LCMV. Considerable infiltration by neutrophils is more characteristic of bacterial and fungal infections, not viral infection 104 . Functional analysis of CD8 + T cells has shown substantial induction of Rorc and T H 17 signature genes (those encoding the IL-23 receptor, IL-17A, IL-21 and IL-22) 104 . Eomes -/-CD8 + T cells do not express IL-17A; however, there is evidence of deregulated expression of signature genes of IL-17-producing cytotoxic T cells (T C 17 cells) in Tbx21 -/-mice, although it is less severe than that seen in Tbx21 −/− Eomes −/− mice 104 . Depletion of CD8 + T cells prevents the virus-induced immunopathology and neutrophilia in Tbx21 -/-Eomes -/-mice, but depletion of CD4 + T cells does not. These results suggest that expression of T-bet and eomesodermin is essential for activation of the CD8 + T cell effector program, which is effective against viral pathogens, and for simultaneous suppression of the T C 17 genetic program, which is involved in defense against extracellular pathogens 104 . More production of IL-17A by Tbx21 -/-CD8 + T cells with accompanying neutrophilia is also observed in autoimmune myocarditis and in the rejection of cardiac allografts 109, 110 . Reminiscent of the role of T-bet in suppressing the T H 17 differentiation program in CD4 + T cells, T-bet expression is also needed to suppress the T C 17 response in CD8 + T cells and prevent the development of T C 17 response-mediated immunopathology.
Analyses of T-bet-deficient mice has shown that T-bet regulates immunoglobulin (IgG) class switching in B cells. T-bet expression in B cells is induced in response to signaling by IFN-g, Toll-like receptor 9 and the costimulatory molecule CD40 and is linked to the induction of IgG2a, IgG2b and IgG3 and repression of IgG1 and IgE 12, 111, 112 . T-bet expression in B cells can be beneficial or detrimental depending on the pathological state. For example, induction of T-bet in B cells can be an efficacious treatment strategy for ameliorating IgE-mediated allergic responses and asthma because T-bet acts as a negative regulator of IgE production 112 . In contrast, higher expression of T-bet in B cells initiates IgG2a class switching. The ability of T-bet to stimulate IgG2a production by B cells is essential for the pathogenesis of mouse lupus 12 . The progeny of T-bet-deficient mice bred onto the lupus-susceptible background are protected from immune-complex glomerulonephritis. These mice have much less glomerular, interstitial and perivascular inflammation and less deposition immune complexes in the kidneys, associated with impaired IgG2a production by Tbx21 -/-B cells. Thus, T-bet expression in B cells can contribute to the generation of pathological autoantibodies on an autoimmunity-susceptible background.
In addition to its role in cells of adaptive immunity, T-bet has critical developmental and functional roles in the innate immune system. T-bet is important for the normal development and survival of NK and NKT cells. Tbx21 -/-NKT cells do not produce IFN-g after stimulation with a-galactosylceramide, and they fail to undergo homeostatic proliferation in response to IL-15 because of their lack of expression of CD122 (the IL-15 receptor b-subunit) 13 . NK cells from T-bet-deficient in initiating and driving disease pathogenesis. Better understanding of how T-bet functions in T cells and other cells of the immune system may allow the development of effective treatments for autoimmune disease without compromising host immune defenses.
DCs is sufficient to induce the pathology of collagen antibody-induced arthritis in T-bet-deficient mice and in Tbx21 -/-Rag2 -/-mice. The effect of T-bet on DC function is dual. In addition to being required for the proper activation of helper T cells, T-bet regulates production of the inflammatory cytokine IL-1a and the chemokine CCL3 (MIP-1a). Thus, less production of IL-1a and CCL3 by DCs contributes to the diminished infiltration of CD4 + T cells and inflammation in T-betdeficient mice 10 . These results suggest that targeting T-bet in DCs could be therapeutically beneficial in the treatment of rheumatoid arthritis.
Concluding remarks and future directions
In the past 25 years, remarkable progress has been made in the understanding of helper T cells. Four unique CD4 + T cell lineages have been identified-T H 1, T H 2, T H 17 and T reg -whose differentiation and functions are regulated by the lineage-specific transcription factors T-bet, GATA-3, RORgt and Foxp3, respectively 2, 3, 52, 94 . Each helper T cell subset is equipped with the ability to produce a distinct panel of effector cytokines. Such specialization ensures that the right types of cells are mobilized to the site of infection and that the appropriate effector mechanisms are activated in response to a specific challenge. However, differentiated T cells remain flexible and, in response to the external milieu, can dynamically change their cytokine profile to that of an opposing lineage; hence, in an affected organ, T H 1-like T H 17 cells or T H 1-like T H 2 cells are often present 119, 120 . In contrast, T H 1 cells seem to be terminally differentiated and, to our knowledge, there have been no reported cases in which fully committed T H 1 cells have been converted into one of the other helper T cell subsets in vivo. The rigidity of the T H 1 phenotype could be attributed to the dominant nature of T-bet, whose re-expression in T H 17 and T H 2 cells in response to IL-12 and/ or type I-type II interferon signaling contributes to epigenetic changes in major cytokine loci and acquisition of the T H 1-like phenotype 119, 120 . T cell flexibility is beneficial to the host, as the immune system can quickly respond to a changing environment. However, the fine line between protective immunity and destructive inflammation-associated pathology must always be balanced. T-bet expression is associated with both. T-bet expression in the immune system is required for protection against infection and anti-tumor immunity; however, high T-bet expression can lead to T H 1-mediated autoimmunity. Conversely, T-bet deficiency can lead to greater susceptibility to T H 2 cell-or T H 17 cellmediated immunopathology. Many animal models have demonstrated that loss of T-bet expression protects the host from developing several different autoimmune diseases, which suggests that silencing Tbx21 could be therapeutic. However, transcription factors are notoriously difficult to target. In addition, the precise 'titration' of T-bet activity to therapeutic but not pathogenic amounts will be technically challenging. Hence, an alternative approach is to develop small-molecule inhibitors that partially block T-bet activity and/or function by identifying and modulating key T-bet-regulated genes that can be targeted pharmacologically. Studies of T-bet in autoimmune diseases have largely focused on its most famous target, IFN-g. However, there is increasing evidence that there is an IFN-g-independent but T-bet-dependent component to the pathogenesis of autoimmune diseases. One key unanswered question about the role of T-bet in autoimmunity is the nature of these other 'pathogenic' downstream effectors.
It is clear that T-bet has a prominent regulatory role in helper T cells. However, T-bet is expressed in several different cell lineages of the hematopoietic system, including DCs, NK cells, NKT cells, B cells and CD8 + T cells. How T-bet expression in these cells contributes to the pathogenesis of autoimmune disease is still poorly understood. In this review, we have attempted to highlight the importance of T-bet expression in other cells of the adaptive and innate immune systems
